AAAAAA
Results:
1-20
|
Results: 20
Authors:
Virgolini, I
Traub, T
Novotny, C
Leimer, M
Fuger, B
Li, SR
Patri, P
Pangerl, T
Angelberger, P
Raderer, M
Andreae, F
Kurtaran, A
Dudczak, R
Citation: I. Virgolini et al., New trends in peptide receptor radioligands, Q J NUCL M, 45(2), 2001, pp. 153-159
Authors:
Becherer, A
Vierhapper, H
Potzi, C
Karanikas, G
Kurtaran, A
Schmaljohann, J
Staudenherz, A
Dudczak, R
Kletter, K
Citation: A. Becherer et al., FDG-PET in adrenocortical carcinoma, CANC BIO R, 16(4), 2001, pp. 289-295
Authors:
Zettinig, G
Prager, G
Kurtaran, A
Passler, C
Breitenseher, M
Niederle, B
Dudczak, R
Citation: G. Zettinig et al., A man with a Tc-99m-pertechnetate-enhancing mediastinal mass, THYROID, 11(8), 2001, pp. 805-805
Authors:
Virgolini, I
Patri, P
Novotny, C
Traub, T
Leimer, M
Fuger, B
Li, SR
Angelberger, P
Raderer, M
Wogritsch, S
Kurtaran, A
Kletter, K
Dudczak, R
Citation: I. Virgolini et al., Comparative somatostatin receptor scintigraphy using In-111-DOTA-lanreotide and In-111-DOTA-Tyr(3)-octreotide versus F-18-FDG-PET for evaluation of somatostatin receptor-mediated radionuclide therapy, ANN ONCOL, 12, 2001, pp. S41-S45
Authors:
Traub, T
Petkov, V
Ofluoglu, S
Pangerl, T
Raderer, M
Fueger, BJ
Schima, W
Kurtaran, A
Dudczak, R
Virgolini, I
Citation: T. Traub et al., In-111-DOTA-lanreotide scintigraphy in patients with tumors of the lung, J NUCL MED, 42(9), 2001, pp. 1309-1315
Authors:
Raderer, M
Kurtaran, A
Scheithauer, W
Fiebiger, W
Weinlaender, G
Oberhuber, G
Citation: M. Raderer et al., Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid, ONCOL-BASEL, 60(2), 2001, pp. 141-145
Authors:
Prager, G
Czerny, C
Kurtaran, A
Passler, C
Scheuba, C
Bieglmayer, C
Niederle, B
Citation: G. Prager et al., Minimally invasive open parathyroidectomy in an endemic goiter area - A prospective study, ARCH SURG, 136(7), 2001, pp. 810-816
Authors:
Virgolini, I
Traub, T
Leimer, M
Novotny, C
Pangerl, T
Ofluoglu, S
Halvadjieva, E
Smith-Jones, P
Flores, J
Li, SR
Angelberger, P
Havlik, E
Andreae, F
Raderer, M
Kurtaran, A
Niederle, B
Dubczak, R
Citation: I. Virgolini et al., New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy, Q J NUCL M, 44(1), 2000, pp. 50-58
Authors:
Raderer, M
Hejna, MHL
Muller, C
Kornek, GV
Kurtaran, A
Virgolini, I
Fiebieger, W
Hamilton, G
Scheithauer, W
Citation: M. Raderer et al., Treatment of hepatocellular cancer with the long acting somatostatin analog lanreotide in vitro and in vivo, INT J ONCOL, 16(6), 2000, pp. 1197-1201
Authors:
Birnbacher, R
Salzer-Muhar, U
Kurtaran, A
Marx, M
Kuhle, S
Pollak, A
Citation: R. Birnbacher et al., Survival after intrauterine myocardial infarction: Noninvasive assessment of myocardial perfusion with Tc-99m-Sestamibi scintigraphy, AM J PERIN, 17(6), 2000, pp. 309-313
Authors:
Penz, M
Kurtaran, A
Vorbeck, F
Oberhuber, G
Raderer, M
Citation: M. Penz et al., Case 2: Myocardial metastases from a carcinoid tumor, J CL ONCOL, 18(7), 2000, pp. 1596-1597
Authors:
Raderer, M
Kurtaran, A
Leimer, M
Angelberger, P
Niederle, B
Vierhapper, H
Vorbeck, F
Hejna, MHL
Scheithauer, W
Pidlich, J
Virgolini, I
Citation: M. Raderer et al., Value of peptide receptor scintigraphy using I-123-vasoactive intestinal peptide and In-111-DTPA-D-Phe(1)-octreotide in 194 carcinoid patients: Vienna university experience, 1993 to 1998, J CL ONCOL, 18(6), 2000, pp. 1331-1336
Authors:
Kurtaran, A
Becherer, A
Pfeffel, F
Muller, C
Traub, T
Schmaljohann, J
Kaserer, K
Raderer, M
Schima, W
Dudczak, R
Kletter, K
Virgolini, I
Citation: A. Kurtaran et al., F-18-Fluorodeoxyglucose (FDG)-PET features of focal nodular hyperplasia (FNH) of the liver, LIVER, 20(6), 2000, pp. 487-490
Authors:
Kurtaran, A
Ofluoglu, S
Traub, T
Tribl, B
Speiser, P
Grabenwoger, F
Schima, W
Dudczak, R
Virgolini, I
Citation: A. Kurtaran et al., An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: Usefulness of hepatobiliary imaging for differential diagnosis, AM J GASTRO, 95(5), 2000, pp. 1367-1368
Authors:
Raderer, M
Valencak, J
Pfeffel, F
Drach, J
Pangerl, T
Kurtaran, A
Hejna, M
Vorbeck, F
Chott, A
Virgolini, I
Citation: M. Raderer et al., Somatostatin receptor expression in primary gastric versus nongastric extranodal B-cell lymphoma of mucosa-associated lymphoid tissue type, J NAT CANC, 91(8), 1999, pp. 716-718
Authors:
Virgolini, I
Kurtaran, A
Angelberger, P
Raderer, M
Havlik, E
Smith-Jones, P
Citation: I. Virgolini et al., "MAURITIUS": Tumour dose in patients with advanced carcinoma, ITAL J GAST, 31, 1999, pp. S227-S230
Authors:
Prager, G
Czerny, C
Kurtaran, A
Passler, C
Scheuba, C
Niederle, B
Citation: G. Prager et al., The value of preoperative localization studies in primary hyperparathyroidism, CHIRURG, 70(10), 1999, pp. 1082-1088
Authors:
Raderer, M
Hamilton, G
Kurtaran, A
Valencak, J
Haberl, I
Hoffmann, O
Kornek, GV
Vorbeck, F
Hejna, MHL
Virgolini, I
Scheithauer, W
Citation: M. Raderer et al., Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results, BR J CANC, 79(3-4), 1999, pp. 535-537
Authors:
Raderer, M
Hejna, MHL
Kurtaran, A
Kornek, GV
Valencak, JB
Oberhuber, G
Vorbeck, F
Virgolini, I
Scheithauer, W
Citation: M. Raderer et al., Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide, AM J GASTRO, 94(1), 1999, pp. 278-279
Authors:
Leimer, M
Kurtaran, A
Smith-Jones, P
Raderer, M
Havlik, E
Angelberger, P
Vorbeck, F
Niederle, B
Herold, C
Virgolini, I
Citation: M. Leimer et al., Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma, J NUCL MED, 39(12), 1998, pp. 2090-2094
Risultati:
1-20
|